Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
26 February 2020 | Story Leonie Bolleurs
Vegetable tunnels
Two vegetable tunnels were recently established on the UFS Bloemfontein Campus to contribute to the fight against food insecurity.

Food insecurity is a problem on university campuses worldwide. The three campuses of the University of the Free State (UFS) are not exempt from this plight. Research findings indicate that more than 64% of students at the university go through periods of hunger.

Annelize Visagie, , from the Division of Student Affairs who is heading the Food Environment Office at the UFS, confirms that food insecurity at higher education institutions is not a new phenomenon.

In a study with first-year students as focus, Visagie found that academic performance declines and coping mechanisms increase as the severity of food insecurity increases.

“Students use different coping mechanisms, with an alarming percentage of students (40,6%) using fasting as an excuse to friends for not having food, 60% of students skipping meals because they do not have enough money, and 43,2% of students being too embarrassed to ask for help.”

Visagie states that various factors contribute to this alarming scenario, with the main reason being that the majority of students come from impoverished economic and social circumstances. This suggests that although students receive NSFAS funding or any other bursary, it is not a guarantee that they are food secure.

Focus on student wellbeing
Aligning with the UFS strategic goal of improving student success and wellbeing, UFS staff is working hard to implement initiatives and obtain sponsorships and food donations to ensure that students do not go hungry.

Members of the university’s Food Environment Project, Drs Johan van Niekerk and JW Swanepoel from the Centre for Sustainable Agriculture, Rural Development and Extension (CENSARDE), and Karen Scheepers from the Division of Student Affairs who is heading KovsieAct partnered to move the existing vegetable tunnels on the UFS experimental farm to the Bloemfontein Campus.

The construction of the tunnels and boxes was financed by Tiger Brands. Professor Michael Rudolph and Dr Evans Muchesa who are involved with the Siyakhana Food Gardens, assisted with the training of students and consultation throughout the project.

The two tunnels (30 m x 10 m each) are covered with netting, and two water tanks with pumps are fitted to provide the necessary irrigation.

Vegetables add value
Dr Swanepoel explains: “In each tunnel there are 20 raised wooden boxes. Each residence received one box where they planted one type of vegetable crop, including Swiss chard, cabbage, carrots, beet, kale, and broccoli.”

Residence Committee members from all on- and off-campus student communities in civic and social-responsibility portfolios, as well as civic and social-responsibility student associations, received the necessary training to plant vegetables.

The vegetables were planted in mid-February and the first harvest is expected around mid-April.

This initiative, which will help students in the near future to keep the hunger pangs at bay in a healthy way, adds to the existing No Student Hungry programme. Visagie says it is important for the university to assist students in making healthy choices and to educate them on decisions to secure nutritional food for themselves.

In addition, the university also received food parcels from Rise Against Hunger, together with donations from organisations such as Gift of the Givers – providing 200 food parcels to students on the Qwaqwa Campus, and the recent donation from Tiger Brands – providing 500 food parcels to students.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept